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Abstract
Background: Macrophage migration inhibitory factor (MIF) is known to amplify the immune response in septic
animal models. Few clinical data support this pro-inflammatory role in septic patients. Renal replacement therapy
(RRT) as adjuvants in the complex therapy of sepsis has been proposed as a possible approach to eliminate
elevated circulating cytokines. Since recent data suggest that MIF can be effectively removed from the circulating
blood pool in patients with chronic kidney disease, we here aimed to investigate whether RRT in septic shock can
lower plasma levels of this pro-inflammatory cytokine in septic shock patients.
Methods: An observational single-center study on an internist intensive care unit (ICU) was conducted. MIF plasma
levels and mortality of n = 25 patients with septic shock were assessed with a previously validated method for
reliable MIF values. The effect of continuous renal replacement therapy (CRRT) on daily MIF levels and mortality was
assessed by comparing patients with and without need for CRRT due to acute kidney injury (AKI).
Results: MIF plasma levels in patients undergoing CRRT due to septic AKI were steadily decreased compared to
those from patients without CRRT hinting at a MIF removal by hemodialysis. MIF release during ICU stay as assessed
by MIFAUC was lower in patients undergoing CRRT, and Kaplan-Meier analysis revealed a distinctly lower mortality in
patients undergoing CRRT. Analysis of daily MIF levels showed that patients who did not survive septic shock
exhibited steadily higher MIF plasma levels and higher MIFAUC compared to those surviving sepsis. Low MIF levels
were closely associated with improved survival.
Conclusions: This is the first study investigating the effect of efficient MIF removal from the plasma pool of
patients with septic shock. Reduction of high circulating MIF by CRRT therapy was accompanied by improved
survival. Thus, targeted removal of MIF from the circulating blood pool might be a promising approach to reduce
mortality in severe sepsis.
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Background
Severe sepsis and septic shock are major causes of mor-
tality and morbidity worldwide [1]. Septic patients often
develop multiple organ dysfunction syndrome (MODS)
that is characterized by an acute functional impairment
of nearly 50 % of patients presenting with septic shock
on an intensive care unit (ICU) develop acute kidney in-
jury (AKI) with the need of (continuous) renal replace-
ment therapy (CRRT) [2]. The activation of multiple
pro-inflammatory mediators is the hallmark in the
pathophysiology of sepsis. It is widely accepted that
hypercytokinemia caused by the inflammatory response
to infection and abnormal tissue oxygen metabolism
play pivotal roles in the pathophysiology of sepsis [3].
Many of these mediators may directly contribute to
organ dysfunction and determine disease severity. The
close relationship between high levels of inflammatory
cytokines in plasma and mortality in septic patients indi-
cates that the activation of inflammatory mediators plays
an important role in the development of organ dysfunc-
tion and is directly associated with sepsis-induced AKI.
To date, there are attempts to reduce hypercytokinemia
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using CRRT with consecutive removal of circulating in-
flammatory mediators in septic patient with AKI.
Whether this may be a beneficial intervention during
sepsis is under intensive investigation, and first small
studies showed improved outcome after cytokine re-
moval in sepsis-induced acute kidney injury [4–8].
Macrophage migration inhibitory factor (MIF) is an
important mediator of severe sepsis and septic shock
[9–11]. MIF is quasi-ubiquitously expressed and stored
in numerous cell types, while specifically secreted from
the pituitary gland upon endotoxemia [10], from im-
mune cells upon inflammatory stimulation, and from se-
lected endothelial and parenchymal cells upon hypoxic,
hyperoxic, and other stress stimuli [12–14]. MIF is a po-
tent upstream regulator of innate immunity through
modulation of TLR4 expression, inflammatory cytokine
induction, and glucocorticoid overriding effects [15, 16].
MIF was demonstrated to be markedly and persistently
up-regulated in patients with gram-negative sepsis and
was associated with parameters of disease severity and
early death [17].
We recently showed that MIF is a plasma component
that can be dialyzed effectively during hemodialysis in
chronically ill patients suffering from end-stage renal
failure [18]. Whether circulating MIF levels are in-
creased in septic patients with AKI and whether CRRT
removes circulating MIF is not known. We here exam-
ined 25 patients on an internal medicine ICU admitted
due to septic shock concerning the removal of MIF from
the circulating plasma pool by continuous veno-venous
hemodialysis (CVVHD) and whether this affected mor-
tality in septic patients.
Methods
Ethics, consent, and permissions
Ethical approval was obtained from the institutional re-
view board (Ethics commission University Hospital
Duesseldorf ), and written informed consent by the pa-
tients or their spouse was given before participating in
the study.
Study population
Twenty-five patients admitted to an academic, interdis-
ciplinary, internist-neurologic intensive care unit due to
septic shock were enrolled. The definition of septic
shock was based on criteria established in the Surviving
Sepsis Campaign (SSC) guidelines [1]. Patients were di-
vided into two groups according to the presence or lack
of acute septic kidney injury with the need for CVVHD.
Standard treatment of patients
After admission to the ICU and confirmation of septic
shock, all patients received standardized intensive care
treatment according to the SSC guidelines [1] including
fluid substitution, antibiotic treatment, vasopressor treat-
ment, and mechanical ventilation, if necessary. In case of
acute respiratory distress syndrome, patients were
treated according to a locally standardized protocol
adopted the SSC guidelines [19]. Patients were dis-
charged from the ICU after fulfillment of standardized
clinical discharge criteria.
Dialysis specific treatment
The need for CRRT therapy was indicated and approved
after medical round by a nephrologist. AKI was defined
by the criteria introduced by the Acute Kidney Injury
Network in 2012 (increase in creatinine by ≥0.3 mg/dl
within 48 h; increase in creatinine to ≥1.5 times baseline,
which have occurred within the prior 7 days; or urine
volume <0.5 ml/kg/h for 6 h) [20]. CRRT was started
based on standardized criteria (anuria, metabolic acid-
osis, increase of serum creatinine or BUN, increase of
serum potassium). Most of the patients underwent dialy-
sis due to anuria and metabolic acidosis. Dialysis was
conducted as a continuous veno-venous hemodialysis
(CVVHD) using citrate as regional anticoagulant. A de-
tailed description of the citrate CVVHD system has been
published earlier [21, 22]. By default, blood flow was
100 ml/min, dialysate flow was 2000 ml/h. Ultrafiltration
rate was adjusted flexibly upon clinical requirements and
was between 0 and 250 ml/h. Citrate and calcium flow
were adjusted flexibly due to plasma and postfilter levels
of ionized calcium. High-flux membranes (AV600S,
polysulfone membranes, surface area 1.4 m2, Fresenius
Medical Care, Germany) were used in all patients, and
dialysis was performed via standard dialysis catheters
inserted into central veins. Cessation of CVVHD treat-
ment was determined after medical round by a neph-
rologist and was usually conducted due to hemodynamic
stabilization and restart of urine production (at least
5 days).
Blood sample collection
After admission to the ICU and confirmation of the
presence of septic shock, the first blood samples were
drawn within the first 24 h of ICU admission (first day
of ICU treatment) and every following 24 h at the same
time of day for maximal 5 days (second, third, fourth,
and fifth day of ICU treatment) or until discharge from
ICU and death, respectively. Blood samples for MIF
measurements were drawn via an arterial catheter into
heparinized tubed.
MIF measurements
Blood samples for determination of MIF plasma levels
were centrifuged immediately at 1000×g for 15 min at
4 °C. Plasma was obtained and frozen at −20 °C until
measurement. MIF plasma levels were determined using
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an enzyme-linked immunosorbent assay (ELISA, R&D,
Minneapolis, USA) as previously described [23–26].
Data collection
Baseline characteristics were assessed and documented
at the first day of enrollment. The simplified acute physi-
ology score (SAPS II) was evaluated on each day [27].
Subsequently, the sequential organ failure assessment
(SOFA) score and the Acute Physiology and Chronic
Health Evaluation II (APACHE II) score were deter-
mined for the daily assessment of organ dysfunction
throughout the ICU stay [28, 29]. The clinical course of
patients was observed in a follow-up period of 30 days.
Statistical analysis
All data were statistically analyzed with a commercially
available software package (GraphPad Prism 6; Graph-
Pad Software, La Jolla, CA, USA). Data are given as
mean and standard error of the mean (SEM) unless indi-
cated otherwise.
Time course of MIF levels was compared by multiple t
test and Holm-Sidak method for correction of multiple
comparisons. The area under the curve of MIF plasma
levels (MIFAUC) from admission until study drop out
(due to discharge, death or end of study) was computed
to approach the dynamic and inter-individually different
conditions of MIF release expected to occur during ICU
stay. MIFAUC was corrected for the number of days of
ICU stay to preserve comparability. Survival analysis was
done by the Kaplan-Meier method and compared by the
log-rank test. The D’Agostino and Pearson omnibus nor-
mality test was used to test all data for normal distribu-
tion. We used the Student t test to compare normally
distributed results of single measurements and the
Mann-Whitney U test to compare non-normally dis-
tributed data. Proportions were compared using the
chi-square test. In all cases, a level of P < 0.05 was con-
sidered statistically significant.
Availability of data and materials
All data presented are available upon request to peter.
luedike@uk-essen.de.
Results
Characteristics of the study population enrolled at the
intensive care unit
Twenty-five patients with septic shock were included in
this prospective study. Sepsis foci were pulmonary infec-
tions (72 %), urogenital infections (16 %) or other sites
of infection (12 %). In 10 patients out of 25, a microbio-
logical pathogen could be identified. Comparing septic
patients with (n = 11) and without the need for CRRT
(n = 14), neither site of infection nor ICU scores (APA-
CHE II, SOFA, SAPS II) depicting disease severity or
laboratory values were significantly different (Table 1).
However, creatinine levels at admission to the ICU were
higher in patients needing CRRT (2.5 ± 0.2 vs. 1.4 ±
0.2 mg/dl, n = 11–14, P < 0.01, Table 1) indicating a higher
incidence of AKI in this group. Basic demographic and
clinical and biochemical characteristics are summarized
in Table 1.
MIF removal from circulating plasma pool of septic
patients by CVVHD is associated with an improved
outcome
During ICU treatment, patients undergoing CRRT due
to septic acute kidney injury showed lower MIF levels
compared to septic patients without the need for CRRT.
The maximum of plasma MIF was reached 24 h after
ICU admission in patients not undergoing CRRT, while
there were no differences in MIF levels during CRRT
(Fig. 1a). MIF levels equalized at day 5 (Fig. 1a). MIFAUC
as a parameter for total amount of circulating MIF
during ICU stay was significantly lower in patients
undergoing CRRT compared to those without the
need for CRRT (41.7 ± 5.4 vs. 59.6 ± 4.2 ng/ml, n =
11–14, P = 0.05, Fig. 1b) demonstrating effective MIF
removal by CRRT. Importantly, MIF levels at admis-
sion did not vary between patients with need for
CRRT and those without (data not shown). Kaplan-
Meier surviving curves showed improved survival for
patients undergoing CRRT and with consecutive lower
MIFAUC (P = 0.0331, log-rank = 4.539) compared to septic
patients without AKI and without CRRT. Efficacy of
CRRT treatment was proofed by decrease of creatinine
levels (Additional file 1: Figure S1).
Sustained lowered MIF levels are associated with
decreased mortality in septic patients
In patients who survived septic shock, MIF plasma levels
during ICU stay were lower compared to patients who
did not survive septic shock (Fig. 2a). MIF release during
ICU stay was significantly lower in patients who sur-
vived septic shock as depicted by MIFAUC (48.3 ± 3 vs.
63.3 ± 5.1 ng/ml, n = 11–14, P < 0.05, Fig. 2b). High
MIFAUC (beyond median, >51.9 ng/ml) was associated
with increased 30-day mortality compared to MIFAUC
(below median, <51.9 ng/ml) as shown by Kaplan-Meier
surviving curves (P = 0.0037, log-rank = 8.43, Fig. 2c).
Discussion
Severe sepsis and septic shock are major health care
problems, affecting millions of people around the world
and killing at least one in four [1]. Improving diagnosis,
optimizing sepsis therapy and thereby limiting high
mortality is the goal of the surviving sepsis campaign.
Renal replacement therapy belongs to supportive sepsis
therapy approaches and should be conducted as CRRT
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Fig. 1 MIF removal from circulating plasma pool of septic patients by CVVHD is associated with an improved outcome. a Septic patients undergoing
CRRT due to septic acute kidney injury showed lower MIF levels compared to septic patients without the need for CRRT during ICU stay. b Total MIF
release during ICU stay as assessed by MIFAUC was lower in patients undergoing CRRT compared to those without the need for CRRT. c Kaplan-Meier
survival curves show increased 30-day mortality for patients without CRRT compared to those undergoing CRRT
Table 1 Patients’ characteristics
Total (n = 25) No CRRT (n = 14) CRRT (n = 11) P value
Age (years) 73 ± 3 74 ± 4 73 ± 4 0.7946
Male (%) 80 85 72 0.5127
APACHE II 26 ± 2 25 ± 2 28 ± 3 0.4645
SAPS II 41 ± 2 39 ± 3 43 ± 3 0.4815
SOFA 9 ± 1 9 ± 1 9 ± 1 0.7636
Mechanical ventilation (%) 76 79 73 0.7872
Need for vasopressors (%) 100 100 100 1
Sites of infection (%)
Lung 72 86 55 0.0849
Urogenital 16 14 18 0.7350
Other 12 7 27 0.7341
Microbiological data (n)
Gram-negative/positive 3/7 3/4 0/3 0.4750
Blood urea nitrogen (mg/dl) 77 ± 8 70 ± 9 86 ± 14 0.3497
Creatinine (mg/dl) 1.8 ± 0.2 1.4 ± 0.2 2.5 ± 0.2 <0.01
WBC (/μl) 11.7 ± 1.4 11.9 ± 2 11.4 ± 2 0.8834
CRP (mg/dl) 16.8 ± 2.6 21 ± 4 12 ± 2 0.1447
PCT (ng/ml) 8.7 ± 3.4 7.8 ± 2.5 10.4 ± 8.8 0.4982
Co-morbidities (%)
Coronary artery disease 28 33 18 0.3895
NYHA IV 4 0 9 0.2496
COPD 27 24 9 0.0620
Pulmonary hypertension 8 7 9 0.8586
Immunosuppression 23 21 27 0.7341
Hepatic disease 8 7 9 0.8586
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to facilitate management of fluid balance and
hemodynamic stabilization [1]. In first small studies,
additional effects of hemodialysis during septic shock
have been investigated. Besides general immunomodu-
latory effects, it has been described that CRRT can be
used as a cytokine modulator since first studies showed
that removal of various pro-inflammatory cytokines
such as TNFα, IL-6 and IL-8 from the bloodstream re-
sulted in early recovery from septic shock [30–32].
MIF is a key mediator of severe sepsis and septic
shock [9–11], and it was demonstrated that MIF levels
are persistently elevated in patients with sepsis, and high
MIF levels were associated with parameters of disease
severity and early death [17]. In experimental sepsis
models, MIF inhibition by MIF antibodies and MIF re-
ceptor antagonists was shown to protect from septic
shock and to improve survival [9, 33, 34]. We recently
showed that hemodialysis is an effective tool to neutralize
circulating MIF by removal from the blood pool in pa-
tients with end-stage renal failure [18]. In the present
study, we show first evidence of the effect of lowering MIF
levels in patients undergoing CRRT in septic shock.
Baseline characteristics of these patients did not differ
except for retention parameters (creatinine) indicating a
higher incidence of AKI in CRRT group as expected.
The measured MIF values in patients with CRRT were
steadily lower compared to patients without CRRT until
reaching a steady state at day 5 hinting at a possible re-
moval by CRRT. Of course, our study remains as a proof
of concept, since the exact mechanism of MIF removal
by CRRT has not been addressed in this study. Our re-
sults are based on isolated measurements of plasma MIF
levels, which reflect a sum of circulating, newly pro-
duced, secreted, and removed as well as degraded MIF.
With our data, it is not possible to distinguish between
production, removal, and degradation rates of MIF.
Nonetheless, it is unlikely that the differences in MIF
levels are due to different production rates. It is more
likely to assume that MIF levels are lowered by CRRT
since conduction of CRRT is the only obvious MIF-
influencing difference between our groups. Furthermore,
our group proofed effective removal of MIF by dialysis
before [18]. In addition, the comparison of decrease of
MIF levels with decrease of creatinine levels during
CRRT showed a close correlation (Additional file 2:
Figure S2) hinting at a similar mechanism.
Overall total amount of circulating MIF during ICU stay
as measured by MIFAUC was significantly lower in CRRT
patients indicating effective removal by hemodialysis.
There is lack of knowledge concerning MIF releasing cell
type, MIF plasma half life and its relation to MIF removal
in patients with septic shock. Furthermore, blood purifica-
tion is a complex topic and intensive studies are needed to
confirm MIF removal and to calculate MIF clearance by
CRRT. Nevertheless, our study shows first evidence that
CRRT in septic shock modulates not only TNFα, IL-6,
and IL-8 levels but also MIF levels to reduce hypercytoki-
nemia with a close correlation to improved survival.
Proof of effective MIF removal gives us two new view-
points on the role of MIF in sepsis: MIF removal by
CRRT is an option to neutralize MIF in septic shock and
since MIF receptor antagonists and MIF antibodies are
not approved for human use yet, CRRT is the only op-
tion for MIF neutralization in humans. None of existing
studies on the role of MIF in sepsis report the overall
incidence of CRRT in the investigated patients, and none
of these studies scrutinized whether CRRT might influ-
ence and confound measured MIF levels.
Moreover, patients receiving CRRT and exhibiting de-
creased MIF levels showed improved survival. Since
47.5 % (95 % CI, 45.2–49.5 %) of patients presenting
with septic shock on ICU develop acute kidney injury
Fig. 2 Sustained lowered MIF levels are associated with decreased mortality in septic patients. a Survivors of septic shock showed lower MIF
plasma levels during ICU stay compared to non-survivors. b Total MIF release was significantly lower in patients who survived septic shock.
c Kaplan-Meier survival curves are displayed, showing that patients with high MIF (MIFAUC >51.9 ng/ml) had an increased short-time mortality at
the ICU compared to those with low MIF (MIFAUC <51.9 ng/ml) during ICU stay
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with the need of CRRT [2], this issue is of great import-
ance. Mortality rates in patients with septic shock are
known to be extraordinarily high. In the present study,
mortality rates showed two peaks with one at a very
early time point and one at around day 10 after admis-
sion (Fig. 1c). Whether this late rise in mortality can be
attributed to the increased MIF levels in this group can-
not be answered yet. Since the development of systemic
inflammatory response syndrome and subsequent devel-
opment of multiple organ dysfunction syndrome appear
to be related to MIF levels and the balance of Th1 and
Th2 function, this might be an explanation for the ob-
served kinetic [35].
Of note, our study has some limitations. It is limited
by its observational approach without providing a prior
power analysis that allows for a distinct statement on
the role of MIF removal by CRRT on mortality. Besides,
a major limitation of this study is the small number of
patients. Larger studies are needed to confirm MIF
neutralization and its effects on improved survival. As
mentioned before, this study did not elucidate the mech-
anism of potential MIF removal by CRRT. Despite these
limitations considering the study design, we can draw
three clear-cut messages from this study.
First, MIF plasma levels can be effectively decreased
by CRRT in septic patients on an ICU. Second, further
studies have to consider CRRT as a critical confounder
concerning the measurement and interpretation of MIF
levels since removal of MIF must be taken into consider-
ation. Third, reduced MIF levels are associated with im-
proved survival of septic shock, and therefore, the
removal of MIF could be a new therapeutic approach for
adjunctive sepsis therapy.
Conclusions
In summary, we here provide first evidence to effectively
influence MIF plasma levels by CRRT in septic patients
with AKI. CRRT with consecutive lowering of MIF levels
was closely associated with survival in those patients and
these preliminary results should be taken into consider-
ation further studies to develop novel concepts of ad-
junctive sepsis therapy.
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